1-20 of 17,852 results for member:"Earl Howe"
Librarians' tools
- Search time
- 0.407 seconds
- Solr query time
- 0.024 seconds
- Search query
- member:"Earl Howe"
- We searched for
- member_ses:301294
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
Lords committee stage first day. Clause 4 agreed to. Clause 5 under consideration. (Part 2 of 2).
Lords committee stage first day. Clause 4 agreed to. Clause 5 under consideration. (Part 2 of 2).
My Lords, I too am grateful to the noble Lord, Lord Rennard, for bringing forward these amendments and for drawing the Committee’s attention to the important issue of diabetes prevention, treatment and care. I particularly welcome the focus in these amendments on innovation, because this is an area in which...
My Lords, I too am grateful to the noble Lord, Lord Rennard, for bringing forward these amendments and for drawing the Committee’s attention to the important issue of diabetes prevention, treatment and care. I particularly welcome the focus in these amendments on innovation, because this is an area in which...
Lords committee stage first day. Clause 1 agreed to. Clause 2, as amended, agreed to. Clause 3 agreed to. Clause 4 under consideration. (Part 1 of 2).
Lords committee stage first day. Clause 1 agreed to. Clause 2, as amended, agreed to. Clause 3 agreed to. Clause 4 under consideration. (Part 1 of 2).
My Lords, it is a pleasure to begin our Committee consideration of the Health Bill, and I look forward to the discussions over the coming days. I am grateful to the Minister and to the Government for bringing forward these amendments, which we understand to be principally technical in nature,...
My Lords, it is a pleasure to begin our Committee consideration of the Health Bill, and I look forward to the discussions over the coming days. I am grateful to the Minister and to the Government for bringing forward these amendments, which we understand to be principally technical in nature,...
Moved by
Earl Howe
4: After Clause 3, insert the following new Clause—
“Abolition of NHS England: transition plan
(1) The Secretary of State must prepare and publish a transition plan in relation to the abolition of NHS England.
(2) The transition plan must set out—
(a) the objectives which the abolition of NHS England is...
Moved by
Earl Howe
4: After Clause 3, insert the following new Clause—
“Abolition of NHS England: transition plan
(1) The Secretary of State must prepare and publish a transition plan in relation to the abolition of NHS England.
(2) The transition plan must set out—
(a) the objectives which the abolition of NHS England is...
My Lords, in moving Amendment 4, I express my appreciation to the noble Lord, Lord Kakkar, for adding his name to it.
I well recognise that Members of the Committee may be taken aback by the monumental size of this amendment, but its size is, to a very real extent, its...
My Lords, in moving Amendment 4, I express my appreciation to the noble Lord, Lord Kakkar, for adding his name to it.
I well recognise that Members of the Committee may be taken aback by the monumental size of this amendment, but its size is, to a very real extent, its...
My Lords, I am grateful to the Minister for her wide-ranging response, and to all noble Lords who have contributed to this important debate, which has been very useful.
The Committee has spoken with one voice in underlining the scale and complexity of the task which lies ahead and the importance...
My Lords, I am grateful to the Minister for her wide-ranging response, and to all noble Lords who have contributed to this important debate, which has been very useful.
The Committee has spoken with one voice in underlining the scale and complexity of the task which lies ahead and the importance...
Moved by
Earl Howe
5: After Clause 3, insert the following new Clause—
“Supply Chain Coordination Limited
(1) Before making a transfer scheme under section 2 which relates to shares held by NHS England in Supply Chain Coordination Limited, the Secretary of State must publish and lay before Parliament a report on the proposed...
Moved by
Earl Howe
5: After Clause 3, insert the following new Clause—
“Supply Chain Coordination Limited
(1) Before making a transfer scheme under section 2 which relates to shares held by NHS England in Supply Chain Coordination Limited, the Secretary of State must publish and lay before Parliament a report on the proposed...
My Lords, Amendment 5 stands in my name and that of my noble friend Lord Kamall. I am grateful to the noble Lord, Lord Hunt of Kings Heath, for his Amendment 211 in this group.
Amendment 5 concerns the future ownership and governance of Supply Chain Co-ordination Limited following the abolition...
My Lords, Amendment 5 stands in my name and that of my noble friend Lord Kamall. I am grateful to the noble Lord, Lord Hunt of Kings Heath, for his Amendment 211 in this group.
Amendment 5 concerns the future ownership and governance of Supply Chain Co-ordination Limited following the abolition...
My Lords, I am grateful to the Minister for her response and to all noble Lords who have contributed to this debate. I am particularly grateful to the noble Lord, Lord Hunt of Kings Heath, for his insights into the performance of the NHS Supply Chain and its current shortcomings....
My Lords, I am grateful to the Minister for her response and to all noble Lords who have contributed to this debate. I am particularly grateful to the noble Lord, Lord Hunt of Kings Heath, for his insights into the performance of the NHS Supply Chain and its current shortcomings....
To ask His Majesty's Government what assessment they have made of the extent to which current ambulatory electrocardiogram tariff arrangements, which do not differentiate by monitoring duration, act as a barrier to NHS adoption of longer-duration monitoring that improves the likelihood of detecting atrial fibrillation.
To ask His Majesty's Government what assessment they have made of the extent to which current ambulatory electrocardiogram tariff arrangements, which do not differentiate by monitoring duration, act as a barrier to NHS adoption of longer-duration monitoring that improves the likelihood of detecting atrial fibrillation.
No such assessment has been made. Electrocardiogram monitoring or stress testing, including 24-hour ambulatory electrocardiography and extended electrocardiographic recording, are currently priced under Healthcare Resource Group (HRG) EY51Z. The NHS Payment Scheme and associated HRG classifications are kept under review to ensure that they support the delivery of effective and efficient patient care.
My Lords, I am grateful to the Leader of the House for allowing time for questions on this Statement. In the other place, my right honourable friend the leader of the Opposition set out some of the serious challenges that we are facing as a country, many of which cannot...
My Lords, I am grateful to the Leader of the House for allowing time for questions on this Statement. In the other place, my right honourable friend the leader of the Opposition set out some of the serious challenges that we are facing as a country, many of which cannot...
My Lords, it is a pleasure for me to open our first discussion on this significant Bill, and I thank the Minister for introducing it in her customary clear way. I do not think she would disagree with me if I described the Bill as a landmark measure, proposing as...
My Lords, it is a pleasure for me to open our first discussion on this significant Bill, and I thank the Minister for introducing it in her customary clear way. I do not think she would disagree with me if I described the Bill as a landmark measure, proposing as...
To ask His Majesty's Government what steps they are taking to ensure that people with atrial fibrillation at high risk of stroke receive anticoagulation medication; and whether this will be reflected in the metrics accompanying the cardiovascular disease modern service framework.
To ask His Majesty's Government what steps they are taking to ensure that people with atrial fibrillation at high risk of stroke receive anticoagulation medication; and whether this will be reflected in the metrics accompanying the cardiovascular disease modern service framework.
To ask His Majesty's Government whether the terms of reference of the Casey Commission on adult social care have been revised following the Prime Minister’s announcement on social care reform; and if so, whether they will publish those terms of reference.
To ask His Majesty's Government whether the terms of reference of the Casey Commission on adult social care have been revised following the Prime Minister’s announcement on social care reform; and if so, whether they will publish those terms of reference.
The terms of reference for the Independent Commission into Adult Social Care will be published shortly to reflect the earlier timetable for Baroness Casey's final report, but there has been no change to the overall objectives of the Commission, or the independent basis on which it is being conducted.
To ask His Majesty's Government what assessment they have made of the additional funding needs of social care reform from (1) reallocation of existing resources, (2) additional service user contributions, or (3) new money to be allocated in future Budget settlements; and what approximate share of total funding each would...
To ask His Majesty's Government what assessment they have made of the additional funding needs of social care reform from (1) reallocation of existing resources, (2) additional service user contributions, or (3) new money to be allocated in future Budget settlements; and what approximate share of total funding each would...
On 29 July, the Prime Minister set out his objectives to reform the social care system and brought forward the timetable for Baroness Casey’s commission to inform that reform programme. We will update Parliament in due course on the proposals resulting from that work, and we will continue working to build a political and public consensus behind those reforms.
To ask His Majesty's Government whether they will intend to confirm detailed plans for social care reform before the next general election, following the Prime Minister’s decision to fast-track Baroness Casey of Blackstock’s review of adult social care.
To ask His Majesty's Government whether they will intend to confirm detailed plans for social care reform before the next general election, following the Prime Minister’s decision to fast-track Baroness Casey of Blackstock’s review of adult social care.
On 29 July, the Prime Minister set out his objectives to reform the social care system and brought forward the timetable for Baroness Casey’s commission to inform that reform programme. We will update Parliament in due course on the proposals resulting from that work, and we will continue working to build a political and public consensus behind those reforms.
To ask His Majesty's Government what assessment they have made of whether current NICE appraisal processes are sufficient responsive to emerging treatments for rare diseases and advanced therapies.
To ask His Majesty's Government what assessment they have made of whether current NICE appraisal processes are sufficient responsive to emerging treatments for rare diseases and advanced therapies.
The Government recognises the importance of patients with rare diseases being able to access effective new medicines. The National Institute for Health and Care Excellence (NICE) assesses whether medicines should be funded by the National Health Service. Its process has been proven to be suitable for rare disease medicines, including advanced therapies, where companies work constructively with NICE and NHS England. Since March 2024, NICE has recommended 89% of the rare disease medicines it has appraised for some or all eligible patients.
To ask His Majesty's Government what assessment they have made of the resilience of NHS medicines supply chains following recent shortages including Creon, insulin, ADHD medicine and blood pressure treatments; and whether they have identified any other medicines considered at particular risk of future disruption.
To ask His Majesty's Government what assessment they have made of the resilience of NHS medicines supply chains following recent shortages including Creon, insulin, ADHD medicine and blood pressure treatments; and whether they have identified any other medicines considered at particular risk of future disruption.
There are approximately 14,000 licensed medicines and the overwhelming majority are in good supply. Medicine supply chains are complex, global and highly regulated and there are several reasons why supply can be disrupted, many of which are not specific to the United Kingdom and outside of Government control. These include manufacturing difficulties, access to raw materials, sudden demand spikes, or distribution and regulatory issues.
The Department uses a sophisticated, multi-layered approach to monitor, assess, and respond to medicines at risk of future supply disruption. Intelligence is drawn from a wide range of sources, including our existing communication channels with our partners in the National Health Service, suppliers, industry, and international partners. In 2020, the Department developed a global risk register which draws on information on medicines licensed in the UK to map manufacturing touchpoints within the supply chain. It is used to help understand medicines supply chains vulnerability and risk.
To ask His Majesty's Government what governance arrangements will oversee the development and implementation of the NHS single patient record; and what independent scrutiny will be applied.
To ask His Majesty's Government what governance arrangements will oversee the development and implementation of the NHS single patient record; and what independent scrutiny will be applied.
The development and implementation of the Single Patient Record (SPR) will be overseen through the governance arrangements for the Transforming and Connecting Care (TCC) Programme. These provide accountability for design and delivery, with oversight from the Senior Responsible Officer, Programme Director and Programme Design Director. The Programme Board will provide overall governance, strategic leadership and decision-making authority.
Delivery will be overseen by the TCC Programme Delivery Group, which will focus on how and when programme outcomes are delivered. Design will be overseen by the TCC Programme Design Authority, which will assure what the programme is delivering, including coherence across products, architecture, clinical safety, cyber security, information governance, policy and transformation. SPR project-level governance will report into these.
Independent scrutiny will be provided through advisory and assurance routes, including the Clinical Advisory Group and the Data Transformation Check and Challenge Group. The programme also engages with external organisations and expert bodies as part of its governance and assurance arrangements, including participation by the National Cyber Security Centre in relevant design authority discussions to provide specialist cyber security expertise and challenge.
These advisory, assurance and external challenge mechanisms will support robust scrutiny throughout the design and implementation of the SPR, complemented by additional independent assurance commissioned at key points in the programme.